Skip to main content
Premium Trial:

Request an Annual Quote

On the Mend or Grasping at Straws?

At Patent Docs, Donald Zuhn says that biotech/pharma IPOs and venture funding are bouncing back. In particular, he points to Cumberland Pharmaceuticals and Seattle Genetics, which are now or soon will be (respectively) trading their common stock, and to
Inspire Pharmaceuticals' announcement of a filing with the Securities and Exchange Commission to offer its stock publicly. For venture funding, Zhun says that there has been a 72 percent increase in biopharmaceutical investing between the first and second quarters of this year.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.